ShockWave Medical price target raised to $360 from $290 at Piper Sandler

Piper Sandler raised the firm’s price target on ShockWave Medical to $360 from $290 and keeps an Overweight rating on the shares. The firm notes ShockWave recently received FDA approval for the company’s next-generation E8 peripheral BTK device and enrollment in the company’s FORWARD PAD IDE also finished ahead of schedule. These devices allow ShockWave to treat additional patient anatomy BTK and, together, Wedbush believes this IVL segment is poised for an acceleration in 2025-2026.